Part 6 — Appendices and Evidence

Part 6 contains the supporting documents, extracts, and reference materials that underpin the findings presented in this case study. 

These appendices provide the clinical, neurological, and safeguarding evidence required to understand the long‑term baseline and the procedural failures identified in the 2026 assessment.

This section is designed for:

• clinicians

• safeguarding professionals

• governance reviewers

• case auditors

• external agencies

Each appendix provides a specific piece of evidence that supports the conclusions set out in Parts 1–5.

6.1 — Extracts from the 2018 Specialist Report

This appendix includes the key findings from the 2018 neuro‑ophthalmology assessment, including:

• confirmation of permanent vertical nystagmus

• impaired gaze stability

• reduced pursuit and saccadic control

• functional‑vision limitations

• spatial‑awareness deficits

• confirmation of lifelong neurological impairment

These findings form the established clinical baseline.

6.1a — Clinical Summary of the 2018 Specialist Report

(Detailed Extract)

The 2018 specialist neuro‑ophthalmology report provides a detailed description of the young person’s permanent neurological visual impairment. The clinician confirms that the impairment has remained unchanged since 1994, with only minor adjustments to spectacle prescription. The report identifies the following key clinical features:

Permanent Visual Impairment

• Visual acuity measured at approximately 6/12 at best.

• A measurable visual impairment present since 1994.

• The impairment is permanent and not amenable to treatment.

Severely Impaired Eye‑Movement Control

• Markedly poor control of eye movements, described as a significant and severe visual impairment in its own right.

• Difficulty locating objects and maintaining fixation.

• Eye movements are slow, inaccurate, and require considerable effort.

• Visual tasks cause rapid fatigue due to the strain of maintaining fixation.

Vertical Nystagmus

• Presence of vertical nystagmus with small, repetitive up‑and‑down movements.

• Nystagmus worsens with tiredness or stress.

• Contributes to instability of vision and difficulty maintaining eye position.

Divergent Strabismus and Alternating Fixation

• The young person cannot use both eyes together.

• They alternate between eyes depending on distance (right eye for distance, left eye for near).

• Eye positioning is inconsistent and difficult to control.

Intractable Diplopia (Double Vision)

• The individual does not suppress the image from either eye.

• In visually complex or low‑light environments, the brain receives conflicting input from both eyes.

• This leads to confusion about object position and increases real‑world risk.

Functional‑Vision Impact

The report explains that the neurological impairment causes:

• Difficulty functioning in busy or fast‑moving environments.

• Significant risk near traffic due to delayed visual processing.

• Difficulty interpreting spatial layout and locating objects in space.

• Poor hand‑eye coordination.

• Exaggerated head posture when concentrating or fatigued, reflecting the effort required to stabilise vision.

Spatial‑Awareness Deficits

• No binocular depth perception due to divergent strabismus.

• Extremely poor spatial perception linked to eye‑movement impairment and nystagmus.

• Difficulty judging distances, object position, and spatial relationships.

Refractive Error Considerations

• High myopic prescription increases visual distortion at the lens edges.

• Poor eye‑movement control makes adapting to these distortions more difficult.

Clinical Conclusion

The specialist concludes that:

• The impairment is lifelong, stable, and non‑fluctuating.

• The neurological features have remained consistent since 1994.

• The impairment is not treatable and not capable of improvement.

• The visual difficulties constitute a real danger in everyday environments.

• This report forms the established clinical baseline for all future assessments.

6.2 — Summary of the 2026 Routine Sight‑Test

Letter (with citations)

The 20 February 2026 letter from the routine Special Assessment Clinic presents findings based solely on an optometric framework. The clinician reports that:

“Your eyes remain stable with short sight that is well‑corrected by your glasses.” “You continue to have an alternating exotropia…”

The letter also states:

“episodes of intermittent nystagmus (when your eyes wobble)”

These statements form the core of the 2026 conclusions.

Key Points Recorded in the 2026 Letter

The clinician reports:

• stable short‑sightedness

• alternating exotropia

• use of right eye for distance and left eye for near

• “intermittent” nystagmus

• difficulties in low light

• symptoms attributed to “previous brain injury”

• suggestion to check sight‑impairment registration

• recommendation for a routine 2‑year follow‑up

What the 2026 Letter Did Not Include

The letter does not:

• reference the 2018 specialist report

• reference the 1994–2018 neurological baseline

• acknowledge permanent vertical nystagmus

• acknowledge severe eye‑movement impairment

• acknowledge intractable diplopia

• assess functional vision

• assess spatial awareness

• measure neurological features

• use a neurovisual framework

• justify the claim of “intermittent” nystagmus

• explain contradictions with the long‑term record

Clinical Contradictions

The 2026 letter contradicts the established neurological baseline in several ways:

1. “Intermittent nystagmus” is clinically impossible

The 2018 specialist report confirms permanent vertical nystagmus, present since 1994. Nystagmus of neurological origin does not come and go.

2. No mention of severe eye‑movement impairment

The 2018 report describes eye‑movement control as:

“very poor… a significant and severe visual impairment in its own right.”

The 2026 letter does not acknowledge this at all.

3. No mention of intractable diplopia

The 2018 report confirms lifelong double vision that cannot be suppressed. The 2026 letter omits this entirely.

4. No functional‑vision assessment

The 2018 report describes real‑world danger, especially near traffic. The 2026 letter does not assess or mention functional risk.

5. No reference to spatial‑awareness impairment

The 2018 report confirms extremely poor spatial perception. The 2026 letter does not assess or mention this.

6. No continuity of care

The clinician does not reference:

• the 30‑year baseline

• the neurological diagnosis

• the specialist findings

• the functional‑vision profile

This breaks governance standards.

Why This Matters

The 2026 letter:

• uses the wrong clinical framework

• omits essential neurological tests

• misinterprets neurological features

• contradicts the long‑term record

• introduces clinically impossible statements

• creates a misleading clinical narrative

• is unsafe for other professionals to rely upon

This concludes Part 6 — Appendices and Evidence (Part 1). The timeline establishes the long‑term clinical baseline and identifies the point at which the 2026 assessment diverged from 33 years of consistent specialist evidence.

To maintain clarity and readability, the remaining appendices continue on the next page.

Next Part 6 — Appendices and Evidence (Part 2)

Design & Copyright Owner Maureen Booth-Martin (MBM) © All rights reserved.